JP2008532487A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008532487A5 JP2008532487A5 JP2007554188A JP2007554188A JP2008532487A5 JP 2008532487 A5 JP2008532487 A5 JP 2008532487A5 JP 2007554188 A JP2007554188 A JP 2007554188A JP 2007554188 A JP2007554188 A JP 2007554188A JP 2008532487 A5 JP2008532487 A5 JP 2008532487A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- fragment
- cancer
- mutation
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000012634 fragment Substances 0.000 claims 38
- 230000035772 mutation Effects 0.000 claims 21
- 102220510527 Retinoic acid receptor alpha_L102Y_mutation Human genes 0.000 claims 19
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 14
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 14
- 206010028980 Neoplasm Diseases 0.000 claims 12
- 102220582002 Phospholipid-transporting ATPase ABCA3_N53Q_mutation Human genes 0.000 claims 12
- 201000011510 cancer Diseases 0.000 claims 12
- 125000003275 alpha amino acid group Chemical group 0.000 claims 11
- 102220320590 rs1554306309 Human genes 0.000 claims 10
- 102220470494 Proteasome subunit beta type-3_M34L_mutation Human genes 0.000 claims 8
- 102220183908 rs9282732 Human genes 0.000 claims 8
- 206010009944 Colon cancer Diseases 0.000 claims 6
- 208000009956 adenocarcinoma Diseases 0.000 claims 6
- 239000002246 antineoplastic agent Substances 0.000 claims 6
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 6
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 6
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 4
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 4
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 4
- 102220492950 Nuclear RNA export factor 1_R91A_mutation Human genes 0.000 claims 4
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 4
- 206010038389 Renal cancer Diseases 0.000 claims 4
- 102220521977 THAP domain-containing protein 1_T28A_mutation Human genes 0.000 claims 4
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 4
- 201000010982 kidney cancer Diseases 0.000 claims 4
- 201000007270 liver cancer Diseases 0.000 claims 4
- 208000014018 liver neoplasm Diseases 0.000 claims 4
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 4
- 102000039446 nucleic acids Human genes 0.000 claims 4
- 108020004707 nucleic acids Proteins 0.000 claims 4
- 150000007523 nucleic acids Chemical class 0.000 claims 4
- 201000002528 pancreatic cancer Diseases 0.000 claims 4
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 4
- 201000009030 Carcinoma Diseases 0.000 claims 3
- 102220497694 Ragulator complex protein LAMTOR4_K51A_mutation Human genes 0.000 claims 3
- 102220469751 Voltage-dependent L-type calcium channel subunit beta-2_G50K_mutation Human genes 0.000 claims 3
- 230000004071 biological effect Effects 0.000 claims 3
- 201000000053 blastoma Diseases 0.000 claims 3
- 201000008184 embryoma Diseases 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 102200016465 rs104894275 Human genes 0.000 claims 3
- 102220267369 rs760252179 Human genes 0.000 claims 3
- 206010005003 Bladder cancer Diseases 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 208000010667 Carcinoma of liver and intrahepatic biliary tract Diseases 0.000 claims 2
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 claims 2
- 206010073069 Hepatic cancer Diseases 0.000 claims 2
- 108060003951 Immunoglobulin Proteins 0.000 claims 2
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 claims 2
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 claims 2
- 102220497574 Leukotriene B4 receptor 1_N52Q_mutation Human genes 0.000 claims 2
- 206010033128 Ovarian cancer Diseases 0.000 claims 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 2
- 229930012538 Paclitaxel Natural products 0.000 claims 2
- 102220489100 Phosphatidylinositol transfer protein alpha isoform_N89L_mutation Human genes 0.000 claims 2
- 102220644061 Prostaglandin E synthase 3_E12V_mutation Human genes 0.000 claims 2
- 206010060862 Prostate cancer Diseases 0.000 claims 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 2
- 108010035587 R13Q Proteins 0.000 claims 2
- 206010061934 Salivary gland cancer Diseases 0.000 claims 2
- 206010041067 Small cell lung cancer Diseases 0.000 claims 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 2
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 2
- 206010047741 Vulval cancer Diseases 0.000 claims 2
- 208000004354 Vulvar Neoplasms Diseases 0.000 claims 2
- 230000001093 anti-cancer Effects 0.000 claims 2
- 208000029742 colonic neoplasm Diseases 0.000 claims 2
- 229940127089 cytotoxic agent Drugs 0.000 claims 2
- 206010017758 gastric cancer Diseases 0.000 claims 2
- 201000010536 head and neck cancer Diseases 0.000 claims 2
- 208000014829 head and neck neoplasm Diseases 0.000 claims 2
- 102000018358 immunoglobulin Human genes 0.000 claims 2
- 238000000338 in vitro Methods 0.000 claims 2
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 claims 2
- 201000002250 liver carcinoma Diseases 0.000 claims 2
- 230000001394 metastastic effect Effects 0.000 claims 2
- 206010061289 metastatic neoplasm Diseases 0.000 claims 2
- 229960001592 paclitaxel Drugs 0.000 claims 2
- 229960004641 rituximab Drugs 0.000 claims 2
- 102220069325 rs141790557 Human genes 0.000 claims 2
- 102220274413 rs143950084 Human genes 0.000 claims 2
- 102220243676 rs1555601019 Human genes 0.000 claims 2
- 102220275989 rs1556435940 Human genes 0.000 claims 2
- 102200092684 rs371769427 Human genes 0.000 claims 2
- 102220041275 rs587778692 Human genes 0.000 claims 2
- 201000003804 salivary gland carcinoma Diseases 0.000 claims 2
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 2
- 206010041823 squamous cell carcinoma Diseases 0.000 claims 2
- 201000011549 stomach cancer Diseases 0.000 claims 2
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims 2
- 201000002510 thyroid cancer Diseases 0.000 claims 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims 2
- 201000005102 vulva cancer Diseases 0.000 claims 2
- 102220491290 Annexin A1_S34A_mutation Human genes 0.000 claims 1
- 102220618022 Arginine-glutamic acid dipeptide repeats protein_S93Y_mutation Human genes 0.000 claims 1
- 102220557487 Caspase-4_Y31A_mutation Human genes 0.000 claims 1
- 102220498105 Electron transfer flavoprotein subunit beta_N53A_mutation Human genes 0.000 claims 1
- 102220486715 Gap junction beta-2 protein_M34A_mutation Human genes 0.000 claims 1
- 102220593911 HLA class I histocompatibility antigen, alpha chain E_V97A_mutation Human genes 0.000 claims 1
- 101001115218 Homo sapiens Ubiquitin-40S ribosomal protein S27a Proteins 0.000 claims 1
- 102220475982 Keratin, type I cytoskeletal 10_Q24A_mutation Human genes 0.000 claims 1
- 102220497573 Leukotriene B4 receptor 1_N52A_mutation Human genes 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 102220486635 Mannose-1-phosphate guanyltransferase beta_S56A_mutation Human genes 0.000 claims 1
- 102220573906 Natural resistance-associated macrophage protein 2_N89A_mutation Human genes 0.000 claims 1
- 102220475756 Probable ATP-dependent RNA helicase DDX6_S30A_mutation Human genes 0.000 claims 1
- 102220500205 Ragulator complex protein LAMTOR4_R29A_mutation Human genes 0.000 claims 1
- 102220474389 Retinoic acid receptor RXR-alpha_S27A_mutation Human genes 0.000 claims 1
- 206010039491 Sarcoma Diseases 0.000 claims 1
- 102220477731 Tumor necrosis factor receptor superfamily member 13C_L28A_mutation Human genes 0.000 claims 1
- 102220469752 Voltage-dependent L-type calcium channel subunit beta-2_G50D_mutation Human genes 0.000 claims 1
- 102220479831 Voltage-dependent L-type calcium channel subunit beta-2_P55K_mutation Human genes 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 230000006907 apoptotic process Effects 0.000 claims 1
- 238000003556 assay Methods 0.000 claims 1
- 229960004562 carboplatin Drugs 0.000 claims 1
- 190000008236 carboplatin Chemical compound 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 230000003013 cytotoxicity Effects 0.000 claims 1
- 231100000135 cytotoxicity Toxicity 0.000 claims 1
- 230000001419 dependent effect Effects 0.000 claims 1
- 239000000539 dimer Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims 1
- 229960005277 gemcitabine Drugs 0.000 claims 1
- 238000001727 in vivo Methods 0.000 claims 1
- 230000006882 induction of apoptosis Effects 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 229960004768 irinotecan Drugs 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 239000003446 ligand Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000006659 positive regulation of apoptotic process Effects 0.000 claims 1
- 102200153431 rs1060501000 Human genes 0.000 claims 1
- 102220164283 rs141738168 Human genes 0.000 claims 1
- 102220244279 rs373241693 Human genes 0.000 claims 1
- 102220098908 rs774768866 Human genes 0.000 claims 1
- 102220280441 rs776730435 Human genes 0.000 claims 1
- 102220072507 rs794729056 Human genes 0.000 claims 1
- 102220100736 rs878854061 Human genes 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
- 230000005909 tumor killing Effects 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US64955005P | 2005-02-02 | 2005-02-02 | |
| US60/649,550 | 2005-02-02 | ||
| US11/344,564 | 2006-01-30 | ||
| US11/344,564 US8029783B2 (en) | 2005-02-02 | 2006-01-30 | DR5 antibodies and articles of manufacture containing same |
| PCT/US2006/003577 WO2006083971A2 (en) | 2005-02-02 | 2006-01-31 | Dr5 antibodies and uses thereof |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012239879A Division JP2013027407A (ja) | 2005-02-02 | 2012-10-31 | Ｄｒ５抗体およびその使用 |
| JP2015091261A Division JP2015133985A (ja) | 2005-02-02 | 2015-04-28 | Ｄｒ５抗体およびその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2008532487A JP2008532487A (ja) | 2008-08-21 |
| JP2008532487A5 true JP2008532487A5 (OSRAM) | 2009-02-26 |
| JP5886509B2 JP5886509B2 (ja) | 2016-03-16 |
Family
ID=36777882
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007554188A Active JP5886509B2 (ja) | 2005-02-02 | 2006-01-31 | Ｄｒ５抗体およびその使用 |
| JP2012239879A Pending JP2013027407A (ja) | 2005-02-02 | 2012-10-31 | Ｄｒ５抗体およびその使用 |
| JP2015091261A Pending JP2015133985A (ja) | 2005-02-02 | 2015-04-28 | Ｄｒ５抗体およびその使用 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012239879A Pending JP2013027407A (ja) | 2005-02-02 | 2012-10-31 | Ｄｒ５抗体およびその使用 |
| JP2015091261A Pending JP2015133985A (ja) | 2005-02-02 | 2015-04-28 | Ｄｒ５抗体およびその使用 |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US8029783B2 (OSRAM) |
| EP (1) | EP1844077B1 (OSRAM) |
| JP (3) | JP5886509B2 (OSRAM) |
| KR (1) | KR101297467B1 (OSRAM) |
| CN (1) | CN101247825B (OSRAM) |
| AT (1) | ATE526987T1 (OSRAM) |
| AU (1) | AU2006210779B2 (OSRAM) |
| BR (1) | BRPI0606891A2 (OSRAM) |
| CA (1) | CA2594918C (OSRAM) |
| ES (1) | ES2374301T3 (OSRAM) |
| IL (1) | IL184617A (OSRAM) |
| MX (1) | MX2007009215A (OSRAM) |
| NO (1) | NO341791B1 (OSRAM) |
| NZ (1) | NZ556478A (OSRAM) |
| RU (1) | RU2458072C2 (OSRAM) |
| WO (1) | WO2006083971A2 (OSRAM) |
Families Citing this family (88)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004003144A2 (en) * | 2002-07-01 | 2004-01-08 | Human Genome Sciences, Inc. | Antibodies that specifically bind to reg iv |
| WO2005092927A1 (en) | 2004-03-23 | 2005-10-06 | Biogen Idec Ma Inc. | Receptor coupling agents and therapeutic uses thereof |
| KR100847010B1 (ko) | 2006-07-05 | 2008-07-17 | 아주대학교산학협력단 | 세포사멸 수용체 5 (ｄｒ5)에 특이적으로 결합하는 항체 및이를 포함하는 암 예방 또는 치료용 조성물 |
| PL4365189T3 (pl) | 2007-07-09 | 2025-05-26 | F. Hoffmann-La Roche Ag | Zapobieganie redukcji wiązania disiarczkowego podczas rekombinacyjnego wytwarzania polipeptydów |
| JPWO2009020094A1 (ja) * | 2007-08-09 | 2010-11-04 | 第一三共株式会社 | 疎水性分子で修飾した抗体 |
| WO2010047509A2 (ko) * | 2008-10-24 | 2010-04-29 | 아주대학교 산학협력단 | 친화도와 안정성이 향상된 항 ｄｒ5 항체, 및 이를 포함하는 암 예방 또는 치료용 조성물 |
| US9365901B2 (en) | 2008-11-07 | 2016-06-14 | Adaptive Biotechnologies Corp. | Monitoring immunoglobulin heavy chain evolution in B-cell acute lymphoblastic leukemia |
| CN102272327B (zh) | 2008-11-07 | 2015-11-25 | 赛昆塔公司 | 通过序列分析监测状况的方法 |
| US9528160B2 (en) | 2008-11-07 | 2016-12-27 | Adaptive Biotechnolgies Corp. | Rare clonotypes and uses thereof |
| US8748103B2 (en) | 2008-11-07 | 2014-06-10 | Sequenta, Inc. | Monitoring health and disease status using clonotype profiles |
| US9506119B2 (en) | 2008-11-07 | 2016-11-29 | Adaptive Biotechnologies Corp. | Method of sequence determination using sequence tags |
| US8628927B2 (en) | 2008-11-07 | 2014-01-14 | Sequenta, Inc. | Monitoring health and disease status using clonotype profiles |
| DK2387627T3 (en) | 2009-01-15 | 2016-07-04 | Adaptive Biotechnologies Corp | Adaptive immunity profiling and methods for producing monoclonal antibodies |
| US20120070432A1 (en) * | 2009-05-28 | 2012-03-22 | Amgen Inc. | Treatment of pancreatic cancer using a dr5 agonist in combination with gemcitabine |
| WO2010146059A2 (en) | 2009-06-16 | 2010-12-23 | F. Hoffmann-La Roche Ag | Biomarkers for igf-1r inhibitor therapy |
| RU2539032C2 (ru) | 2009-06-25 | 2015-01-10 | Фред Хатчинсон Кансэр Рисёч Сентер | Способ измерения искусственного иммунитета |
| WO2011004899A1 (en) * | 2009-07-06 | 2011-01-13 | Takeda Pharmaceutical Company Limited | Cancerous disease modifying antibodies |
| HRP20200768T4 (hr) * | 2009-08-11 | 2025-03-28 | F. Hoffmann - La Roche Ag | Proizvodnja proteina u mediju za uzgoj stanica bez glutamina |
| GB0914691D0 (en) | 2009-08-21 | 2009-09-30 | Lonza Biologics Plc | Immunoglobulin variants |
| JP2013505944A (ja) * | 2009-09-24 | 2013-02-21 | シアトル ジェネティックス， インコーポレイテッド | Ｄｒ５リガンド薬物結合体 |
| PT2483310E (pt) * | 2009-09-29 | 2014-10-07 | Roche Glycart Ag | Anticorpos bi-específicos agonistas do receptor de morte |
| KR20120101050A (ko) | 2009-11-05 | 2012-09-12 | 더 유에이비 리서치 파운데이션 | 기저형 유전자형 암의 치료 방법 |
| WO2011084623A1 (en) | 2009-12-16 | 2011-07-14 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Method of sensitizing cancer cells to the cytotoxic effects of death receptor ligands in cancer treatment |
| NZ602368A (en) | 2010-02-12 | 2014-10-31 | Pharmascience Inc | Iap bir domain binding compounds |
| EP2569336A1 (en) * | 2010-05-14 | 2013-03-20 | Amgen Inc. | Enhanced death receptor agonists |
| CN103154026B (zh) * | 2010-08-05 | 2016-07-06 | 安奈普泰斯生物有限公司 | 抗il-17的抗体 |
| RU2644678C1 (ru) | 2010-10-29 | 2018-02-13 | Дайити Санкио Компани, Лимитед | Новое антитело против dr5 |
| WO2012106281A2 (en) | 2011-01-31 | 2012-08-09 | The General Hospital Corporation | Multimodal trail molecules and uses in cellular therapies |
| JP6130307B2 (ja) | 2011-03-17 | 2017-05-17 | ザ ユニバーシティ オブ バーミンガム | 再指向性免疫療法 |
| CA2834776A1 (en) * | 2011-05-03 | 2012-11-08 | Genentech, Inc. | Therapeutic apo2l/trail polypeptides and death receptor agonist antibodies |
| US10385475B2 (en) | 2011-09-12 | 2019-08-20 | Adaptive Biotechnologies Corp. | Random array sequencing of low-complexity libraries |
| HK1201565A1 (en) | 2011-10-21 | 2015-09-04 | Adaptive Biotechnologies Corporation | Quantification of adaptive immune cell genomes in a complex mixture of cells |
| EP2788509B1 (en) | 2011-12-09 | 2018-07-11 | Adaptive Biotechnologies Corporation | Diagnosis of lymphoid malignancies and minimal residual disease detection |
| US9499865B2 (en) | 2011-12-13 | 2016-11-22 | Adaptive Biotechnologies Corp. | Detection and measurement of tissue-infiltrating lymphocytes |
| ES2662128T3 (es) | 2012-03-05 | 2018-04-05 | Adaptive Biotechnologies Corporation | Determinación de cadenas de receptor inmunitario emparejadas a partir de la frecuencia de subunidades coincidentes |
| HK1206760A1 (en) * | 2012-03-28 | 2016-01-15 | Amgen Inc. | Dr5 receptor agonist combinations |
| US9150905B2 (en) | 2012-05-08 | 2015-10-06 | Adaptive Biotechnologies Corporation | Compositions and method for measuring and calibrating amplification bias in multiplexed PCR reactions |
| US9500639B2 (en) | 2012-07-18 | 2016-11-22 | Theranos, Inc. | Low-volume coagulation assay |
| WO2014018113A1 (en) | 2012-07-24 | 2014-01-30 | The General Hospital Corporation | Oncolytic virus therapy for resistant tumors |
| WO2014035474A1 (en) * | 2012-08-30 | 2014-03-06 | The General Hospital Corporation | Compositions and methods for treating cancer |
| JP6449160B2 (ja) | 2012-10-01 | 2019-01-09 | アダプティブ バイオテクノロジーズ コーポレイション | 適応免疫受容体多様性およびクローン性特性決定による免疫能力評価関連出願の相互参照 |
| WO2015160439A2 (en) | 2014-04-17 | 2015-10-22 | Adaptive Biotechnologies Corporation | Quantification of adaptive immune cell genomes in a complex mixture of cells |
| UA118028C2 (uk) | 2013-04-03 | 2018-11-12 | Рош Глікарт Аг | Біспецифічне антитіло, специфічне щодо fap і dr5, антитіло, специфічне щодо dr5, і спосіб їх застосування |
| CA2910877C (en) * | 2013-05-03 | 2021-08-03 | Fujifilm Diosynth Biotechnologies Uk Limited | Expression process |
| US9708657B2 (en) | 2013-07-01 | 2017-07-18 | Adaptive Biotechnologies Corp. | Method for generating clonotype profiles using sequence tags |
| KR102306493B1 (ko) | 2013-11-25 | 2021-09-28 | 씨젠 인크. | 접합을 위한 ｃｈｏ 세포 배양물로부터의 항체 제조 |
| ES2741740T3 (es) | 2014-03-05 | 2020-02-12 | Adaptive Biotechnologies Corp | Métodos que usan moléculas sintéticas que contienen segmentos de nucleótidos aleatorios |
| WO2015138638A1 (en) | 2014-03-11 | 2015-09-17 | Theraly Pharmaceuticals, Inc. | Long acting trail receptor agonists for treatment of autoimmune diseases |
| US10066265B2 (en) | 2014-04-01 | 2018-09-04 | Adaptive Biotechnologies Corp. | Determining antigen-specific t-cells |
| US9616114B1 (en) | 2014-09-18 | 2017-04-11 | David Gordon Bermudes | Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity |
| EP3715455A1 (en) | 2014-10-29 | 2020-09-30 | Adaptive Biotechnologies Corp. | Highly-multiplexed simultaneous detection of nucleic acids encoding paired adaptive immune receptor heterodimers from many samples |
| US10246701B2 (en) | 2014-11-14 | 2019-04-02 | Adaptive Biotechnologies Corp. | Multiplexed digital quantitation of rearranged lymphoid receptors in a complex mixture |
| CA2968543C (en) | 2014-11-25 | 2024-04-02 | Adaptive Biotechnologies Corporation | Characterization of adaptive immune response to vaccination or infection using immune repertoire sequencing |
| SG11201705632UA (en) * | 2015-01-08 | 2017-08-30 | Kyowa Hakko Kirin Co Ltd | Bispecific antibody binding to trailr2 and psma |
| DK3247728T3 (da) | 2015-01-20 | 2020-07-13 | Igm Biosciences Inc | Tumornekrosefaktor-(tnf)-superfamiliereceptorbindende molekyler og anvendelser deraf |
| TW201627322A (zh) * | 2015-01-26 | 2016-08-01 | 宏觀基因股份有限公司 | 抗-ｄｒ５抗體和包括其ｄｒ５-結合結構域的分子 |
| SG11201706024YA (en) | 2015-01-26 | 2017-08-30 | Macrogenics Inc | Multivalent molecules comprising dr5-binding domains |
| US11047008B2 (en) | 2015-02-24 | 2021-06-29 | Adaptive Biotechnologies Corporation | Methods for diagnosing infectious disease and determining HLA status using immune repertoire sequencing |
| WO2016161273A1 (en) | 2015-04-01 | 2016-10-06 | Adaptive Biotechnologies Corp. | Method of identifying human compatible t cell receptors specific for an antigenic target |
| US10676723B2 (en) | 2015-05-11 | 2020-06-09 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
| WO2017028279A1 (en) * | 2015-08-19 | 2017-02-23 | Beijing Cotimes Biotech Company Limited | Trail receptor-binding agents and uses of same |
| US10407510B2 (en) | 2015-10-30 | 2019-09-10 | Genentech, Inc. | Anti-factor D antibodies and conjugates |
| KR102791773B1 (ko) * | 2015-10-30 | 2025-04-03 | 갤럭시 바이오테크, 엘엘씨 | 사멸 수용체 4 및 사멸 수용체 5에 결합하는 매우 강력한 항체 |
| US11007251B2 (en) | 2015-12-17 | 2021-05-18 | The Johns Hopkins University | Ameliorating systemic sclerosis with death receptor agonists |
| WO2017139485A1 (en) | 2016-02-09 | 2017-08-17 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Method of sensitizing cancer cells to the cytotoxic effects of apoptosis inducing ligands in cancer treatment |
| CN109195620B (zh) * | 2016-04-07 | 2022-06-28 | 约翰霍普金斯大学 | 用死亡受体激动剂治疗胰腺炎和疼痛的组合物和方法 |
| US10428325B1 (en) | 2016-09-21 | 2019-10-01 | Adaptive Biotechnologies Corporation | Identification of antigen-specific B cell receptors |
| US11129906B1 (en) | 2016-12-07 | 2021-09-28 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
| US11180535B1 (en) | 2016-12-07 | 2021-11-23 | David Gordon Bermudes | Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria |
| EP3360898A1 (en) | 2017-02-14 | 2018-08-15 | Boehringer Ingelheim International GmbH | Bispecific anti-tnf-related apoptosis-inducing ligand receptor 2 and anti-cadherin 17 binding molecules for the treatment of cancer |
| KR101926834B1 (ko) | 2017-03-21 | 2018-12-07 | 동아에스티 주식회사 | 항-dr5 항체 및 그의 용도 |
| WO2019000105A1 (en) | 2017-06-30 | 2019-01-03 | Zymeworks Inc. | STABILIZED CHIMERIC FABES |
| KR101951025B1 (ko) * | 2017-08-17 | 2019-02-21 | 서울대학교산학협력단 | 세포사멸 수용체 저해제를 유효성분으로 포함하는 cx3cl1 케모카인 과발현으로 인한 질환 예방 또는 치료용 조성물 |
| CN109810193B (zh) * | 2017-11-21 | 2020-11-03 | 深圳市中科艾深医药有限公司 | 抗dr5的抗体及其制备方法和应用 |
| CN109810194B (zh) * | 2017-11-21 | 2020-11-03 | 深圳市中科艾深医药有限公司 | 抗dr5的抗体及其制备方法和应用 |
| WO2019100194A1 (zh) * | 2017-11-21 | 2019-05-31 | 深圳先进技术研究院 | 抗dr5的抗体及其制备方法和应用 |
| WO2019100193A1 (zh) * | 2017-11-21 | 2019-05-31 | 深圳先进技术研究院 | 抗dr5的抗体及其制备方法和应用 |
| US11254980B1 (en) | 2017-11-29 | 2022-02-22 | Adaptive Biotechnologies Corporation | Methods of profiling targeted polynucleotides while mitigating sequencing depth requirements |
| CN109957025A (zh) * | 2017-12-25 | 2019-07-02 | 深圳宾德生物技术有限公司 | 一种靶向dr5的单链抗体、嵌合抗原受体t细胞及其制备方法和应用 |
| GB201800994D0 (en) * | 2018-01-22 | 2018-03-07 | Ucl Business Plc | Combination therapeutics |
| US12018045B2 (en) | 2018-03-06 | 2024-06-25 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | 17-beta-hydroxywithanolides and use thereof in treating cancer |
| US12378529B2 (en) * | 2018-06-13 | 2025-08-05 | Genex Health Co., Ltd | Method for culturing colorectal cancer solid tumor primary cells and colorectal cancer ascites primary tumor cells and supporting reagents |
| CN119896730A (zh) | 2018-12-17 | 2025-04-29 | 雷维托普有限公司 | 双免疫细胞衔接物 |
| US20240382499A1 (en) | 2021-01-15 | 2024-11-21 | Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis | Inducers of senescence, in combination with a selective death receptor 5 (dr5) agonist, for use in a method of treating cancer |
| CN113493510A (zh) * | 2021-07-07 | 2021-10-12 | 上海交通大学 | 一种牛源抗金黄色葡萄球菌LukD毒力因子的单链抗体及其制备和应用 |
| CN117285643A (zh) | 2022-06-16 | 2023-12-26 | 清华大学 | 一种相变调节套件及其用途 |
| WO2025098480A1 (zh) * | 2023-11-10 | 2025-05-15 | 信达生物制药(苏州)有限公司 | 抗dr5和ceacam5的双特异性抗体及其用途 |
| WO2025149667A1 (en) | 2024-01-12 | 2025-07-17 | Pheon Therapeutics Ltd | Antibody drug conjugates and uses thereof |
Family Cites Families (97)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2413974A1 (fr) | 1978-01-06 | 1979-08-03 | David Bernard | Sechoir pour feuilles imprimees par serigraphie |
| WO1981001145A1 (en) | 1979-10-18 | 1981-04-30 | Univ Illinois | Hydrolytic enzyme-activatible pro-drugs |
| US4342566A (en) | 1980-02-22 | 1982-08-03 | Scripps Clinic & Research Foundation | Solid phase anti-C3 assay for detection of immune complexes |
| US4419446A (en) | 1980-12-31 | 1983-12-06 | The United States Of America As Represented By The Department Of Health And Human Services | Recombinant DNA process utilizing a papilloma virus DNA as a vector |
| US4873191A (en) | 1981-06-12 | 1989-10-10 | Ohio University | Genetic transformation of zygotes |
| US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
| US4601978A (en) | 1982-11-24 | 1986-07-22 | The Regents Of The University Of California | Mammalian metallothionein promoter system |
| US4560655A (en) | 1982-12-16 | 1985-12-24 | Immunex Corporation | Serum-free cell culture medium and process for making same |
| US4657866A (en) | 1982-12-21 | 1987-04-14 | Sudhir Kumar | Serum-free, synthetic, completely chemically defined tissue culture media |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
| US4767704A (en) | 1983-10-07 | 1988-08-30 | Columbia University In The City Of New York | Protein-free culture medium |
| US4736866A (en) | 1984-06-22 | 1988-04-12 | President And Fellows Of Harvard College | Transgenic non-human mammals |
| US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
| GB8516415D0 (en) | 1985-06-28 | 1985-07-31 | Celltech Ltd | Culture of animal cells |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| US4927762A (en) | 1986-04-01 | 1990-05-22 | Cell Enterprises, Inc. | Cell culture medium with antioxidant |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| GB8705477D0 (en) | 1987-03-09 | 1987-04-15 | Carlton Med Prod | Drug delivery systems |
| US4975278A (en) | 1988-02-26 | 1990-12-04 | Bristol-Myers Company | Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells |
| DE68925971T2 (de) | 1988-09-23 | 1996-09-05 | Cetus Oncology Corp | Zellenzuchtmedium für erhöhtes zellenwachstum, zur erhöhung der langlebigkeit und expression der produkte |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5047335A (en) | 1988-12-21 | 1991-09-10 | The Regents Of The University Of Calif. | Process for controlling intracellular glycosylation of proteins |
| DE69029036T2 (de) | 1989-06-29 | 1997-05-22 | Medarex Inc | Bispezifische reagenzien für die aids-therapie |
| DE10399023I2 (de) | 1989-09-12 | 2006-11-23 | Ahp Mfg B V | TFN-bindende Proteine |
| US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US5278229A (en) * | 1990-02-01 | 1994-01-11 | Nippon Gohsei Kagaku Kogyo Kabushiki Kaisha | Polyolefin composition and the use thereof |
| AU8507191A (en) | 1990-08-29 | 1992-03-30 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5122469A (en) | 1990-10-03 | 1992-06-16 | Genentech, Inc. | Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins |
| CA2095633C (en) | 1990-12-03 | 2003-02-04 | Lisa J. Garrard | Enrichment method for variant proteins with altered binding properties |
| US5278299A (en) | 1991-03-18 | 1994-01-11 | Scripps Clinic And Research Foundation | Method and composition for synthesizing sialylated glycosyl compounds |
| EP0940468A1 (en) | 1991-06-14 | 1999-09-08 | Genentech, Inc. | Humanized antibody variable domain |
| EP0605522B1 (en) | 1991-09-23 | 1999-06-23 | Medical Research Council | Methods for the production of humanized antibodies |
| WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
| WO1993010260A1 (en) | 1991-11-21 | 1993-05-27 | The Board Of Trustees Of The Leland Stanford Junior University | Controlling degradation of glycoprotein oligosaccharides by extracellular glycosisases |
| JPH08500017A (ja) | 1992-08-17 | 1996-01-09 | ジェネンテク，インコーポレイテッド | 二特異的免疫アドヘジン |
| DE69303494T2 (de) | 1992-11-13 | 1997-01-16 | Idec Pharma Corp | Therapeutische verwendung von chimerischen und markierten antikörper gegen menschlichen b lymphozyt beschränkter differenzierung antigen für die behandlung von b-zell-lymphoma |
| CA2163032C (en) | 1993-06-03 | 2001-02-06 | John Landon | Antibody fragments in therapy |
| ES2233936T3 (es) | 1994-02-04 | 2005-06-16 | Bio Merieux | Virus msrv1 asociado a la esclerosis en placas, sus constituyentes nucleicos y sus aplicaciones. |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US5739277A (en) | 1995-04-14 | 1998-04-14 | Genentech Inc. | Altered polypeptides with increased half-life |
| US6113898A (en) | 1995-06-07 | 2000-09-05 | Idec Pharmaceuticals Corporation | Human B7.1-specific primatized antibodies and transfectomas expressing said antibodies |
| US6284236B1 (en) | 1995-06-29 | 2001-09-04 | Immunex Corporation | Cytokine that induces apoptosis |
| KR100510234B1 (ko) | 1995-06-29 | 2005-11-25 | 임뮤넥스 코포레이션 | 세포소멸을 유도하는 시토킨 |
| US6030945A (en) | 1996-01-09 | 2000-02-29 | Genentech, Inc. | Apo-2 ligand |
| US6998116B1 (en) | 1996-01-09 | 2006-02-14 | Genentech, Inc. | Apo-2 ligand |
| EP0939804B2 (en) | 1996-10-25 | 2011-06-15 | Human Genome Sciences, Inc. | NEUTROKINE alpha |
| KR20000057560A (ko) | 1996-12-13 | 2000-09-25 | 요시다 다까시 | 폴리에스테르카르보네이트-폴리우레탄우레아 섬유 |
| DE951551T1 (de) | 1996-12-23 | 2000-09-14 | Immunex Corp., Seattle | Ligand für rezeptor aktivator of nf-kappa b, ligand ist mitglied der tnf superfamilie |
| US6433147B1 (en) | 1997-01-28 | 2002-08-13 | Human Genome Sciences, Inc. | Death domain containing receptor-4 |
| ES2284199T5 (es) | 1997-01-28 | 2011-11-14 | Human Genome Sciences, Inc. | Receptor 4 que contiene dominio de muerte (dr4: receptor 4 de muerte), miembro de la superfamilia de receptores de tnf y unión a trail (apo-2l). |
| US6072047A (en) | 1997-02-13 | 2000-06-06 | Immunex Corporation | Receptor that binds trail |
| US20020160446A1 (en) * | 2000-11-14 | 2002-10-31 | Holtzman Douglas A. | Novel genes encoding proteins having prognostic diagnostic preventive therapeutic and other uses |
| US20010010924A1 (en) | 1997-03-14 | 2001-08-02 | Keith Charles Deen | Tumor necrosis factor related receptor, tr6 polynecleotides |
| US6313269B1 (en) | 1997-03-14 | 2001-11-06 | Smithkline Beecham Corporation | Tumor necrosis factor related receptor, TR6 |
| US6872568B1 (en) | 1997-03-17 | 2005-03-29 | Human Genome Sciences, Inc. | Death domain containing receptor 5 antibodies |
| ES2281126T3 (es) | 1997-03-17 | 2007-09-16 | Human Genome Sciences, Inc. | Receptor 5 que contiene un dominio de muerte. |
| RO128635A2 (ro) | 1997-04-16 | 2013-07-30 | Amgen Inc. | Anticorp sau fragment al acestuia care se leagă la opgbp şi utilizarea acestuia, utilizarea unei forme solubile de odar, şi metodă de identificare a unui compus care descreşte activitatea opgbp |
| EP1007562A4 (en) | 1997-04-16 | 2000-09-27 | Millennium Pharm Inc | TANGO-63d AND TANGO-63e PROTEINS RELATED TO THE TUMOR NECROSIS FACTOR RECEPTOR |
| US5896768A (en) * | 1997-05-15 | 1999-04-27 | Ut Automotive Dearborn, Inc. | Electronic child security door lock system |
| US6342369B1 (en) | 1997-05-15 | 2002-01-29 | Genentech, Inc. | Apo-2-receptor |
| ATE516354T1 (de) | 1997-05-15 | 2011-07-15 | Genentech Inc | Apo-2-rezeptor |
| AU8400398A (en) | 1997-07-11 | 1999-02-08 | Trustees Of The University Of Pennsylvania, The | Nucleic acid encoding a novel chemotherapy-induced protein, and methods of use |
| JP2001514888A (ja) | 1997-08-15 | 2001-09-18 | アイドゥン ファーマシューティカルズ， インコーポレイテッド | Ｔｒａｉｌレセプター、これをコードする核酸、およびその使用方法 |
| AU9376498A (en) | 1997-09-05 | 1999-03-22 | University Of Washington | Tumor necrosis factor family receptors and ligands, encoding nucleic acids and related binding agents |
| ES2316182T3 (es) | 1998-01-15 | 2009-04-01 | Genentech, Inc. | Ligando apo-2. |
| US6468532B1 (en) | 1998-01-22 | 2002-10-22 | Genentech, Inc. | Methods of treating inflammatory diseases with anti-IL-8 antibody fragment-polymer conjugates |
| ATE517125T1 (de) | 1998-01-26 | 2011-08-15 | Genentech Inc | ANTIKÖRPER GEGEN ßDEATH RECEPTOR 4ß (DR4) UND DEREN VERWENDUNGEN |
| IL139419A0 (en) | 1998-06-12 | 2001-11-25 | Genentech Inc | Monoclonal antibodies, cross-reactive antibodies and method for producing the same |
| US6252050B1 (en) | 1998-06-12 | 2001-06-26 | Genentech, Inc. | Method for making monoclonal antibodies and cross-reactive antibodies obtainable by the method |
| KR101077001B1 (ko) * | 1999-01-15 | 2011-10-26 | 제넨테크, 인크. | 효과기 기능이 변화된 폴리펩티드 변이체 |
| GB9908533D0 (en) * | 1999-04-14 | 1999-06-09 | Novartis Ag | Organic compounds |
| WO2000073349A1 (en) | 1999-05-28 | 2000-12-07 | Genentech, Inc. | Dr4 antibodies and uses thereof |
| WO2000075191A2 (en) | 1999-06-09 | 2000-12-14 | Genentech, Inc. | Apo-2L RECEPTOR AGONIST AND CPT-11 SYNERGISM |
| IL147029A0 (en) | 1999-06-28 | 2002-08-14 | Genentech Inc | Method for making apo-2 ligand using divalent metal ions |
| JP5111707B2 (ja) | 2000-01-20 | 2013-01-09 | ペルストープ・フランス | 微着色分岐ポリイソシアネートの取得法、及び得られる組成物 |
| JP2001259961A (ja) | 2000-03-15 | 2001-09-25 | Disco Abrasive Syst Ltd | 加工装置 |
| US7279160B2 (en) | 2000-05-02 | 2007-10-09 | The Uab Research Foundation | Combinations of DR5 antibodies and other therapeutic agents |
| TWI318983B (en) | 2000-05-02 | 2010-01-01 | Uab Research Foundation | An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof |
| WO2002009755A2 (en) | 2000-07-27 | 2002-02-07 | Genentech, Inc. | Apo-2l receptor agonist and cpt-11 synergism |
| US7960670B2 (en) * | 2005-05-03 | 2011-06-14 | Kla-Tencor Corporation | Methods of and apparatuses for measuring electrical parameters of a plasma process |
| US7115717B2 (en) | 2001-05-18 | 2006-10-03 | Kirin Beer Kabushiki Kaisha | Anti-TRAIL-R antibodies |
| ES2437992T3 (es) | 2001-05-25 | 2014-01-15 | Human Genome Sciences, Inc. | Anticuerpos que se unen inmunoespecíficamente a los receptores de TRAIL |
| CA2451680C (en) | 2001-07-03 | 2011-04-19 | Genentech, Inc. | Human dr4 antibodies and uses thereof |
| IL161686A0 (en) | 2001-11-01 | 2004-09-27 | Uab Research Foundation | Combinations of antibodies selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and other therapeutic agents |
| ES2357225T3 (es) | 2001-11-01 | 2011-04-20 | Uab Research Foundation | Combinaciones de anticuerpos anti-dr5 y anticuerpos anti-dr4 y otros agentes terapéuticos. |
| AU2002352676A1 (en) | 2001-11-14 | 2003-05-26 | Human Genome Sciences, Inc. | Antibodies that immunospecifically bind to trail receptors |
| CA2471140A1 (en) | 2001-12-20 | 2003-07-03 | Human Genome Sciences, Inc. | Antibodies that immunospecifically bind to trail receptors |
| US8784821B1 (en) | 2003-05-31 | 2014-07-22 | Amgen Research (Munich) Gmbh | Human-anti-human cd3 binding molecules |
| KR20070010046A (ko) | 2004-04-06 | 2007-01-19 | 제넨테크, 인크. | Ｄｒ5 항체 및 그의 용도 |
| JO3000B1 (ar) * | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
| PE20071101A1 (es) | 2005-08-31 | 2007-12-21 | Amgen Inc | Polipeptidos y anticuerpos |
| CN101074261A (zh) | 2006-04-30 | 2007-11-21 | 北京同为时代生物技术有限公司 | Trail受体1和/或trail受体2特异性抗体及其应用 |
-
2006
- 2006-01-30 US US11/344,564 patent/US8029783B2/en active Active
- 2006-01-31 AU AU2006210779A patent/AU2006210779B2/en not_active Ceased
- 2006-01-31 NZ NZ556478A patent/NZ556478A/en not_active IP Right Cessation
- 2006-01-31 AT AT06734171T patent/ATE526987T1/de active
- 2006-01-31 KR KR1020077019924A patent/KR101297467B1/ko active Active
- 2006-01-31 EP EP06734171A patent/EP1844077B1/en active Active
- 2006-01-31 WO PCT/US2006/003577 patent/WO2006083971A2/en not_active Ceased
- 2006-01-31 ES ES06734171T patent/ES2374301T3/es active Active
- 2006-01-31 BR BRPI0606891-0A patent/BRPI0606891A2/pt not_active Application Discontinuation
- 2006-01-31 CA CA2594918A patent/CA2594918C/en active Active
- 2006-01-31 CN CN200680009970.1A patent/CN101247825B/zh active Active
- 2006-01-31 JP JP2007554188A patent/JP5886509B2/ja active Active
- 2006-01-31 MX MX2007009215A patent/MX2007009215A/es active IP Right Grant
- 2006-01-31 RU RU2007132876/10A patent/RU2458072C2/ru active
- 2006-10-10 US US11/546,133 patent/US8030023B2/en active Active
-
2007
- 2007-07-15 IL IL184617A patent/IL184617A/en active IP Right Grant
- 2007-08-31 NO NO20074446A patent/NO341791B1/no unknown
-
2011
- 2011-09-07 US US13/227,391 patent/US8409570B2/en active Active
-
2012
- 2012-10-31 JP JP2012239879A patent/JP2013027407A/ja active Pending
-
2015
- 2015-04-28 JP JP2015091261A patent/JP2015133985A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008532487A5 (OSRAM) | ||
| RU2007132876A (ru) | Антитела к dr5 и их применения | |
| JP7682789B2 (ja) | Ｂ７－Ｈ３のＩｇＶドメインに対するモノクローナル抗体及びその使用 | |
| JP7118117B2 (ja) | 抗体－薬物コンジュゲートの選択的製造方法 | |
| Lou et al. | Antibody variable region engineering for improving cancer immunotherapy | |
| TWI708788B (zh) | 雙特異性抗體 | |
| JP5324593B2 (ja) | マクロファージ刺激タンパク質受容体（ｒｏｎ）の阻害およびその処置の方法 | |
| JP2020503001A5 (OSRAM) | ||
| JP2017500028A (ja) | 新規の抗ｄｐｅｐ３抗体および使用方法 | |
| JP7440509B2 (ja) | Ｃｄｃｐ１－標的化療法 | |
| KR20240145470A (ko) | 항-tigit 항체 및 항-pd-1/항-vegfa 이중특이적 항체를 포함하는 약제학적 조성물 및 용도 | |
| JP2013527762A5 (OSRAM) | ||
| EP4190816A1 (en) | Anti-cd47 monoclonal antibody and use thereof | |
| JPWO2021139777A5 (OSRAM) | ||
| CN106714822A (zh) | 用于治疗癌症的组合治疗 | |
| CN115210261A (zh) | 抗半乳糖凝集素-9抗体及其用途 | |
| US20230340119A1 (en) | Composition of triax antibodies and method of making and using thereof | |
| TW201605480A (zh) | 抗ｅｆｎａ４抗體－藥物結合物 | |
| JP2022550364A (ja) | 新規抗ｐｄ－ｌ１／抗ｌａｇ－３二重特異性抗体およびその使用 | |
| JP2024509501A (ja) | 新規活性を持つｈｈｌａ２結合剤 | |
| JPWO2020218951A5 (OSRAM) | ||
| JP2022554270A (ja) | 抗ｐｄ－１抗体による癌を治療する方法 | |
| EP4406552A1 (en) | Use of anti-cd40 antibody | |
| RU2024126025A (ru) | Антитела против msln и способы их применения | |
| Albrecht | Role of antibodies in cancer treatment (an overview) |